The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study

European Journal of Medical Research

Masoumeh Hosseinzadeh Emam¹  Samrand Fattah Ghazi²  SaeedReza Jamali Moghaddam³  Fereshteh Ghiasvand⁴  Mohammadreza Salehi⁴  Nasim Khajavi Rad⁵  Sayed Hamidreza Abtahi⁶  Maryam Moradi⁷  Mahdi Barkhori Mehni⁸  Mohammadmehdi Akbarian⁸  Omid Moradi Moghaddam⁹ 

[1] Department of Anesthesiology, Critical Care Medicine Subspecialty Fellowship, Iran University Medical Sciences, Tehran, Iran;Department of Anesthesiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran;Department of Infectious Disease, School of Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran;Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran;Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran;Department of Internal Medicine, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran;School of Medicine, Iran University of Medical Sciences, Tehran, Iran;School of Medicine, Tehran University of Medical Sciences, Tehran, Iran;Trauma and Injury Research Center, Critical Care Medicine Department, Iran University of Medical Sciences, Tehran, Iran;

关键词: COVID-19;    Intravenous immunoglobulin;    IVIG;    Pneumonia;    Coronavirus;    Pandemic;   

DOI  :  10.1186/s40001-022-00637-8

来源: Springer

【 摘 要 】

BackgroundDuring the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients.MethodsIn this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate.ResultsThe duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01).ConclusionOur data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate.

【 授权许可】

CC BY